TLOG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLOG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TetraLogic Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2016 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
For the Biotechnology subindustry, TetraLogic Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TetraLogic Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where TetraLogic Pharmaceuticals's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
TetraLogic Pharmaceuticals (OTCPK:TLOG) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Hudson Bay Capital Management Lp | other: See Remarks | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Lazard Asset Management Llc | other: See Remarks | 30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112 |
Nomura Holdings Inc | other: See Remarks | 1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645 |
Whitebox Multi-strategy Partners Lp | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Pandora Select Partners, L.p. | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Whitebox General Partner Llc | other: See Remarks | 3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416 |
Highbridge Capital Management Llc | other: See Remarks | 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172 |
Sander Gerber | other: See Remarks | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Whitebox Concentrated Convertible Arbitrage Partners, L.p. | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Whitebox Advisors Llc | other: See Remarks | 3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416 |
Patrick Hutchison | officer: CFO & Treasurer | C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803 |
Clarus Ventures Ii, Llc | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Clarus Lifesciences Ii, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Clarus Ventures Ii Gp, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Nicholas Simon | 10 percent owner | 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.